首次无诱因静脉血栓栓塞症停用抗凝治疗后症状性复发长期风险:系统评价与荟萃分析
该系统评价与荟萃分析纳入18项研究共7515例首次无诱因静脉血栓栓塞症且完成至少3个月抗凝治疗的患者,评估停药后症状性复发的长期风险。停药后复发率第1年每100人年10.3次事件,第2年6.3次,第3-5年每年3.8次,第6-10年每年3.1次;累积复发率2年16%、5年25%、10年36%。男性10年累积复发率41%高于女性29%;近端深静脉血栓和肺栓塞合并深静脉血栓的复发率高于孤立性肺栓塞。复发事件致死率4%。作者认为这些估计可为临床实践指南提供依据,增强向患者交代预后的信心,并帮助指导无诱因静脉血栓栓塞症的长期管理决策。
要点
- 首次无诱因静脉血栓栓塞症完成至少3个月抗凝后停药,复发率第1年每100人年10.3次事件(95%CI 8.6-12.1),第2年6.3次(5.1-7.7)。
- 累积复发率2年16%(95%CI 13%-19%)、5年25%(21%-29%)、10年36%(28%-45%),复发事件致死率4%(2%-6%)。
- 男性第1年复发率每100人年11.9次(9.6-14.4)高于女性8.9次(6.8-11.3),10年累积复发率男性41%(28%-56%)高于女性29%(20%-38%)。
- 近端深静脉血栓(率比1.4,95%CI 1.1-1.7)和肺栓塞合并深静脉血栓(率比1.5,1.1-1.9)的复发率高于孤立性肺栓塞。
- 远端深静脉血栓停药后第1年复发率每100人年1.9次事件(95%CI 0.5-4.3)。
适用人群与场景
- 首次无诱因静脉血栓栓塞症事件且已完成至少3个月抗凝治疗、随后停用抗凝治疗的患者。
- 纳入随机对照试验和前瞻性队列研究,报告停药后症状性复发性静脉血栓栓塞症。
研究设计与关键结果
- 系统评价与荟萃分析,纳入18项研究共7515例患者,数据来源Medline、Embase和Cochrane Central Register of Controlled Trials(自建库至2019年3月15日)。
- 停药后复发率每100人年:第1年10.3次事件(95%CI 8.6-12.1),第2年6.3次(5.1-7.7),第3-5年每年3.8次(3.2-4.5),第6-10年每年3.1次(1.7-4.9)。
- 累积复发率:2年16%(95%CI 13%-19%),5年25%(21%-29%),10年36%(28%-45%)。
- 男性第1年复发率每100人年11.9次(95%CI 9.6-14.4)vs 女性8.9次(6.8-11.3);10年累积复发率男性41%(28%-56%)vs 女性29%(20%-38%)。
- 与孤立性肺栓塞相比,近端深静脉血栓的复发率比为1.4(95%CI 1.1-1.7),肺栓塞合并深静脉血栓为1.5(1.1-1.9)。
- 远端深静脉血栓停药后第1年复发率每100人年1.9次事件(95%CI 0.5-4.3)。
- 复发性静脉血栓栓塞症的致死率为4%(95%CI 2%-6%)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入随机对照试验和前瞻性队列研究,采用随机效应模型合并数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些估计可为临床实践指南提供依据,增强向患者交代预后的信心,并帮助指导无诱因静脉血栓栓塞症的长期管理决策。
- 原文未据此给出具体抗凝疗程或停药决策推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort studies reporting symptomatic recurrent VTE after discontinuation of anticoagulant treatment in patients with a first unprovoked VTE event who had completed at least three months of treatment.
DATA EXTRACTION AND SYNTHESIS: Two investigators independently screened studies, extracted data, and appraised risk of bias. Data clarifications were sought from authors of eligible studies. Recurrent VTE events and person years of follow-up after discontinuation of anticoagulant treatment were used to calculate rates for individual studies, and data were pooled using random effects meta-analysis. Sex and site of initial VTE were investigated as potential sources of between study heterogeneity.
RESULTS: 18 studies involving 7515 patients were included in the analysis. The pooled rate of recurrent VTE per 100 person years after discontinuation of anticoagulant treatment was 10.3 events (95% confidence interval 8.6 to 12.1) in the first year, 6.3 (5.1 to 7.7) in the second year, 3.8 events/year (95% confidence interval 3.2 to 4.5) in years 3-5, and 3.1 events/year (1.7 to 4.9) in years 6-10. The cumulative incidence for recurrent VTE was 16% (95% confidence interval 13% to 19%) at 2 years, 25% (21% to 29%) at 5 years, and 36% (28% to 45%) at 10 years. The pooled rate of recurrent VTE per 100 person years in the first year was 11.9 events (9.6 to 14.4) for men and 8.9 events (6.8 to 11.3) for women, with a cumulative incidence for recurrent VTE of 41% (28% to 56%) and 29% (20% to 38%), respectively, at 10 years. Compared to patients with isolated pulmonary embolism, the rate of recurrent VTE was higher in patients with proximal deep vein thrombosis (rate ratio 1.4, 95% confidence interval 1.1 to 1.7) and in patients with pulmonary embolism plus deep vein thrombosis (1.5, 1.1 to 1.9). In patients with distal deep vein thrombosis, the pooled rate of recurrent VTE per 100 person years was 1.9 events (95% confidence interval 0.5 to 4.3) in the first year after anticoagulation had stopped. The case fatality rate for recurrent VTE was 4% (95% confidence interval 2% to 6%).
CONCLUSIONS: In patients with a first episode of unprovoked VTE who completed at least three months of anticoagulant treatment, the risk of recurrent VTE was 10% in the first year after treatment, 16% at two years, 25% at five years, and 36% at 10 years, with 4% of recurrent VTE events resulting in death. These estimates should inform clinical practice guidelines, enhance confidence in counselling patients of their prognosis, and help guide decision making about long term management of unprovoked VTE.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42017056309.
参考来源
- Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019. PMID: 31340984. doi:10.1136/bmj.l4363
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。